Cited by 1,077Liver Disease Diagnosis and TreatmentDiet, Metabolism, and DiseaseAlcohol Consumption and Health Effects

The DOI matches its Crossref record; 195 of the 196 references it cites were found in a registry or an index.

Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites†

Open access

Neuschwander‐Tetri, Brent A.·2010·Hepatology

Open this paper in CoChat — free account Open PDF

Abstract

A significant body of evidence now forces us to rethink the causes of NASH. Once thought to be a disease caused by triglyceride accumulation in hepatocytes with subsequent oxidant stress and lipid peroxidation causing inflammation and fibrosis, new data from animal studies and a limited number of human studies now provide convincing evidence that triglyceride accumulation does not cause insulin resistance or cellular injury in the liver. The lipotoxic liver injury hypothesis for the pathogenesis of NASH suggests that we need to focus our therapeutic efforts on reducing the burden of fatty acids going to the liver or being synthesized in the liver. This can be accomplished by improving insulin sensitivity at the level of adipose tissue to prevent inappropriate peripheral lipolysis and by preventing unnecessary de novo lipogenesis in the liver. Excess carbohydrates are the major substrates for de novo lipogenesis, and thus, reducing carbohydrate consumption through dietary changes and increasing muscle glucose uptake through exercise remain important cornerstones of treatment and prevention of lipotoxic liver injury, a disease hitherto called NASH.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1002/hep.23719

Cites

195 of 195 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Steatohepatitis: A tale of two “hits”?
Day, C. P., & James, O. F. W. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70599-2 · Cited by 4,285
Autophagy regulates lipid metabolism
Singh, R., Kaushik, S., Wang, Y., Xiang, Y., Novak, I., Komatsu, M., Tanaka, K., Cuervo, A. M., & Czaja, M. J. (2009) · Nature · doi:10.1038/nature07976 · Cited by 3,975
Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604
Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes.
Guilherme, A., Virbasius, J. V., Puri, V., & Czech, M. P. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2391 · Cited by 2,292
Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation
Watanabe, M., Houten, S. M., Mataki, C., Christoffolete, M. A., Kim, B. W., Sato, H., Messaddeq, N., Harney, J. W., Ezaki, O., Kodama, T., et al. (2006) · Nature · doi:10.1038/nature04330 · Cited by 2,220
Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities
Sanyal, A. J., Campbell–Sargent, C., Mirshahi, F., Rizzo, W. B., Contos, M. J., Sterling, R. K., Luketic, V. A., Shiffman, M. L., & Clore, J. N. (2001) · Gastroenterology · doi:10.1053/gast.2001.23256 · Cited by 2,078
Triglyceride accumulation protects against fatty acid-induced lipotoxicity
Listenberger, L. L., Han, X., Lewis, S. E., Cases, S., Farese, R. V., Ory, D. S., & Schaffer, J. E. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0630588100 · Cited by 2,075
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827
Nonalcoholic Fatty Liver Disease: Predictors of Nonalcoholic Steatohepatitis and Liver Fibrosis in the Severely Obese
Dixon, J. B., Bhathal, P. S., & O’Brien, P. E. (2001) · Gastroenterology · doi:10.1053/gast.2001.25540 · Cited by 1,369
A lipidomic analysis of nonalcoholic fatty liver disease
Puri, P., Baillie, R. A., Wiest, M. M., Mirshahi, F., Choudhury, J., Cheung, O., Sargeant, C., Contos, M. J., & Sanyal, A. J. (2007) · Hepatology · doi:10.1002/hep.21763 · Cited by 1,338

Flagged first, then by citations

Show all 196 references

1 of the 196 references couldn’t be matched to a known paper.

Sorted by citations

Mechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354
Self-citation
The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
Chalasani, N., Younossi, Z. M., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K. J., Charlton, M., & Sanyal, A. J. (2012) · Hepatology · doi:10.1002/hep.25762 · Cited by 3,854
The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)
Buzzetti, E., Pinzani, M., & Tsochatzis, E. A. (2016) · Metabolism · doi:10.1016/j.metabol.2015.12.012 · Cited by 3,119
AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease
Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667
Self-citation
The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology
Chalasani, N., Younossi, Z. M., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K. J., Charlton, M., & Sanyal, A. J. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.04.001 · Cited by 1,805
Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives
Roehlen, N., Crouchet, E., & Baumert, T. F. (2020) · Cells · doi:10.3390/cells9040875 · Cited by 1,237
NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice
Mridha, A. R., Wree, A., Robertson, A. A. B., Yeh, M. M., Johnson, C. D., Van Rooyen, D. M., Haczeyni, F., Teoh, N. C.-H., Savard, C., Ioannou, G. N., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.01.022 · Cited by 1,110
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial
Cusi, K., Orsak, B., Bril, F., Lomonaco, R., Hecht, J., Ortiz-Lopez, C., Tio, F., Hardies, J., Darland, C., Musi, N., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m15-1774 · Cited by 1,024
The interaction of hepatic lipid and glucose metabolism in liver diseases
Bechmann, L. P., Hannivoort, R. A., Gerken, G., Hotamışlıgil, G. S., Trauner, M., & Canbay, A. E. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.08.025 · Cited by 1,033
The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Kazankov, K., Jørgensen, S. M. D., Thomsen, K. L., Møller, H. J., Vilstrup, H., George, J., Schuppan, D., & Grønbæk, H. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0082-x · Cited by 941
Triggering and resolution of inflammation in NASH
Schuster, S., Cabrera, D., Arrese, M., & Feldstein, A. E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0009-6 · Cited by 943
Trends in insulin resistance: insights into mechanisms and therapeutic strategy
Li, M., Chi, X., Wang, Y., Setrerrahmane, S., Xie, W., & Xu, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01073-0 · Cited by 939
Role of Obesity and Lipotoxicity in the Development of Nonalcoholic Steatohepatitis: Pathophysiology and Clinical Implications
Cusi, K. J. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.02.003 · Cited by 940
Nonalcoholic fatty liver disease
Brunt, E. M., Wong, V. W., Nobili, V., Day, C. P., Sookoian, S. C., Maher, J. J., Bugianesi, E., Sirlin, C. B., Neuschwander‐Tetri, B. A., & Rinella, M. E. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.80 · Cited by 889
Self-citation
Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis
Marengo, A., Rosso, C., & Bugianesi, E. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-090514-013832 · Cited by 757
Lipidomics for studying metabolism
Han, X. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.98 · Cited by 727
Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis
Schwabe, R. F., Tabas, I., & Pajvani, U. B. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.311 · Cited by 671
Metabolic-associated fatty liver disease and lipoprotein metabolism
Heeren, J., & Scheja, L. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101238 · Cited by 692
Impaired autophagic flux is associated with increased endoplasmic reticulum stress during the development of NAFLD
González‐Rodríguez, Á., Mayoral, R., Agra, N., Valdecantos, M. P., Pardo, V., Miquilena-Colina, M. E., Vargas‐Castrillón, J., Iacono, O. L., Corazzari, M., Fimia, G. M., et al. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.162 · Cited by 621
Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum
Hardy, T., Oakley, F., Anstee, Q. M., & Day, C. P. (2016) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044224 · Cited by 641
The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
Chalasani, N., Younossi, Z. M., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K. J., Charlton, M., & Sanyal, A. J. (2012) · The American Journal of Gastroenterology · doi:10.1038/ajg.2012.128 · Cited by 594
Recent insights into the pathogenesis of nonalcoholic fatty liver disease
Arab, J. P., Arrese, M., & Trauner, M. (2018) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-020117-043617 · Cited by 573
Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications
Francque, S., van der Graaff, D., & Kwanten, W. J. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.04.005 · Cited by 591
Metabolic syndrome increases the risk of primary liver cancer in the United States: A study in the SEER-medicare database
Welzel, T. M., Graubard, B. I., Zeuzem, S., El‐Serag, H. B., Davila, J. A., & McGlynn, K. A. (2011) · Hepatology · doi:10.1002/hep.24397 · Cited by 539
Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation
Porras, D., Nistal, E., Martínez‐Flórez, S., Pisonero‐Vaquero, S., Olcoz, J. L., Jover, R., González‐Gallego, J., García‐Mediavilla, M. V., & Sánchez‐Campos, S. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.11.037 · Cited by 534
The Role of Cholesterol in the Pathogenesis of NASH
Ioannou, G. N. (2016) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2015.11.008 · Cited by 498
Pathophysiology of obesity and its associated diseases
Jin, X., Qiu, T., Li, L., Yu, R., Chen, X., Li, C., Proud, C. G., & Jiang, T. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.01.012 · Cited by 603
Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH
Pierantonelli, I., & Svegliati‐Baroni, G. (2018) · Transplantation · doi:10.1097/tp.0000000000002480 · Cited by 473
Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease
Lomonaco, R., Ortiz‐Lopez, C., Orsak, B., Webb, A., Hardies, J., Darland, C., Finch, J., Gastaldelli, A., Harrison, S. A., Tio, F. O., et al. (2011) · Hepatology · doi:10.1002/hep.25539 · Cited by 460
Non-alcoholic fatty liver disease
Neuschwander‐Tetri, B. A. (2017) · BMC Medicine · doi:10.1186/s12916-017-0806-8 · Cited by 470
Self-citation
Nonalcoholic Fatty Liver Disease and the Heart
Stahl, E. P., Dhindsa, D. S., Lee, S. K., Sandesara, P. B., Chalasani, N., & Sperling, L. S. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.050 · Cited by 482
Nonalcoholic fatty liver disease: molecular mechanisms for the hepatic steatosis
Koo, S. (2013) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2013.19.3.210 · Cited by 421
Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis
Musso, G., Gambino, R., & Cassader, M. (2012) · Progress in Lipid Research · doi:10.1016/j.plipres.2012.11.002 · Cited by 415
Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease
Rotman, Y., & Sanyal, A. J. (2016) · Gut · doi:10.1136/gutjnl-2016-312431 · Cited by 420
The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans
Benhamed, F., Denechaud, P.-D., Lemoine, M., Robichon, C., Moldes, M., Bertrand-Michel, J., Ratziu, V., Serfaty, L., Housset, C., Capeau, J., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci41636 · Cited by 408
Obesity and cancer: inflammation bridges the two
Kolb, R. H., Sutterwala, F. S., & Zhang, W. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.07.005 · Cited by 431
NASH is an Infl ammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications
Farrell, G. C., Rooyen, D. M. V., Gan, L. T., & Chitturi, S. (2012) · Gut and Liver · doi:10.5009/gnl.2012.6.2.149 · Cited by 408
The NLRP3 inflammasome: Mechanism of action, role in disease and therapies
Wang, L., & Hauenstein, A. V. (2020) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2020.100889 · Cited by 426
Molecular pathways in non-alcoholic fatty liver disease
Auguet, T., Berlanga, A., Guiu‐Jurado, E., & Porras, J. A. (2014) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s62831 · Cited by 395
Evolving Concepts in the Pathogenesis of NASH: Beyond Steatosis and Inflammation
Peverill, W., Powell, L. W., & Skoien, R. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15058591 · Cited by 387
Adaptive immunity: an emerging player in the progression of NAFLD
Sutti, S., & Albano, E. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0210-2 · Cited by 374
The contribution of endoplasmic reticulum stress to liver diseases
Dara, L., Ji, C., & Kaplowitz, N. (2011) · Hepatology · doi:10.1002/hep.24279 · Cited by 373
Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)
Xu, X., Poulsen, K. L., Wu, L., Liu, S., Miyata, T., Song, Q., Wei, Q., Zhao, C., Lin, C., & Yang, J. B. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01119-3 · Cited by 387
Pathological Features of Fatty Liver Disease
Yeh, M. M., & Brunt, E. M. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.07.056 · Cited by 352
Hepatic Free Cholesterol Accumulates in Obese, Diabetic Mice and Causes Nonalcoholic Steatohepatitis
Rooyen, D. M. V., Larter, C. Z., Haigh, W. G., Yeh, M. M., Ioannou, G. N., Kuver, R., Lee, S. P., Teoh, N., & Farrell, G. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.06.040 · Cited by 349
Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial
Patel, K., Harrison, S. A., Elkhashab, M., Trotter, J. F., Herring, R., Rojter, S. E., Kayali, Z., Wong, V. W., Greenbloom, S., Jayakumar, S., et al. (2020) · Hepatology · doi:10.1002/hep.31205 · Cited by 347
GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease
Loomba, R., Kayali, Z., Noureddin, M., Ruane, P., Lawitz, E. J., Bennett, M., Wang, L., Harting, E., Tarrant, J. M., McColgan, B. J., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.07.027 · Cited by 340
Pathophysiology of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
Manne, V., Handa, P., & Kowdley, K. V. (2017) · Clinics in Liver Disease · doi:10.1016/j.cld.2017.08.007 · Cited by 347
Loss of Junctional Adhesion Molecule A Promotes Severe Steatohepatitis in Mice on a Diet High in Saturated Fat, Fructose, and Cholesterol
Rahman, K., Desai, C., Iyer, S. S., Thorn, N. E., Kumar, P., Liu, Y., Smith, T., Neish, A. S., Li, H., Tan, S., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.06.022 · Cited by 346
Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment
Smith, B. W., & Adams, L. A. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.72 · Cited by 334
Pathogenesis and Prevention of Hepatic Steatosis.
Nassir, F., Rector, R. S., Hammoud, G. M., & Ibdah, J. A. (2015) · PubMed Central · Cited by 317
Differential Roles of Unsaturated and Saturated Fatty Acids on Autophagy and Apoptosis in Hepatocytes
Mei, S., Ni, H., Manley, S., Bockus, A. B., Kassel, K. M., Luyendyk, J. P., Copple, B. L., & Ding, W. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.184341 · Cited by 325
A vicious circle between insulin resistance and inflammation in nonalcoholic fatty liver disease
Chen, Z., Yu, R., Xiong, Y., Du, F.-T., & Zhu, S. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0572-9 · Cited by 325
Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors
Francque, S., Szabo, G., Abdelmalek, M. F., Byrne, C. D., Cusi, K., Dufour, J.-F., Roden, M., Sacks, F., & Tacke, F. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00366-5 · Cited by 316
Low Doses of Bisphenol A Induce Gene Expression Related to Lipid Synthesis and Trigger Triglyceride Accumulation in Adult Mouse Liver
Marmugi, A., Ducheix, S., Lasserre, F., Polizzi, A., Paris, A., Priymenko, N., Bertrand‐Michel, J., Pineau, T., Guillou, H., Martin, P. G. P., et al. (2011) · Hepatology · doi:10.1002/hep.24685 · Cited by 317
AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions
Lonardo, A., Nascimbeni, F., Targher, G., Bernardi, M., Bonino, F., Bugianesi, E., Casini, A., Gastaldelli, A., Marchesini, G., Marra, F., et al. (2017) · Digestive and Liver Disease · doi:10.1016/j.dld.2017.01.147 · Cited by 313
Diet-induced mouse model of fatty liver disease and nonalcoholic steatohepatitis reflecting clinical disease progression and methods of assessment
Clapper, J. R., Hendricks, M. D., Gu, G., Wittmer, C., Dolman, C. S., Herich, J., Athanacio, J., Villescaz, C., Ghosh, S. S., Heilig, J. S., et al. (2013) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00079.2013 · Cited by 294
Non-alcoholic fatty liver disease
Smith, B. W., & Adams, L. A. (2011) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2011.596521 · Cited by 300
Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease
Bril, F., Barb, D., Portillo-Sánchez, P., Biernacki, D., Lomonaco, R., Suman, A., Weber, M. H., Budd, J. T., Lupi, M. E., & Cusi, K. J. (2016) · Hepatology · doi:10.1002/hep.28985 · Cited by 291
Evolution of NAFLD and Its Management
Mundi, M. S., Velapati, S. R., Patel, J. R., Kellogg, T. A., Dayyeh, B. K. A., & Hurt, R. T. (2019) · Nutrition in Clinical Practice · doi:10.1002/ncp.10449 · Cited by 299
Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals
Suppli, M. P., Rigbolt, K. T. G., Veidal, S. S., Heebøll, S., Eriksen, P. L., Demant, M., Bagger, J. I., Nielsen, J. C., Oró, D., Thrane, S. W., et al. (2019) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00358.2018 · Cited by 288
Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats
Harriman, G., Greenwood, J., Bhat, S., Huang, X., Wang, R., Paul, D., Tong, L., Saha, A. K., Westlin, W. F., Kapeller, R., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1520686113 · Cited by 287
Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
Spengler, E. K., & Loomba, R. S. (2015) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.06.013 · Cited by 294
Increased expression of cytochrome P450 2E1 in nonalcoholic fatty liver disease: Mechanisms and pathophysiological role
Aubert, J., Begriche, K., Knockaert, L., Robin, M., & Fromenty, B. (2011) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2011.04.015 · Cited by 294
Nonalcoholic Fatty Liver Disease and Hypercholesterolemia: Roles of Thyroid Hormones, Metabolites, and Agonists
Sinha, R. A., Bruinstroop, E., Singh, B. K., & Yen, P. M. (2019) · Thyroid · doi:10.1089/thy.2018.0664 · Cited by 275
Signal Transducer and Activator of Transcription 3 in Liver Diseases: A Novel Therapeutic Target
Wang, H., Lafdil, F., Kong, X., & Gao, B. (2011) · International Journal of Biological Sciences · doi:10.7150/ijbs.7.536 · Cited by 270
Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches
Schuppan, D., & Schattenberg, J. M. (2013) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12212 · Cited by 256
Advances in Pediatric Nonalcoholic Fatty Liver Disease†
Loomba, R. S., Sirlin, C. B., Schwimmer, J. B., & Lavine, J. E. (2009) · Hepatology · doi:10.1002/hep.23119 · Cited by 262
Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets
Fisher, F. M., Chui, P. C., Nasser, I. A., Popov, Y., Cunniff, J. C., Lundasen, T., Kharitonenkov, A., Schuppan, D., Flier, J. S., & Maratos-Flier, E. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.07.044 · Cited by 263
Current efforts and trends in the treatment of NASH
Ratziu, V., Goodman, Z. D., & Sanyal, A. J. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.041 · Cited by 268
Chronic intermittent hypoxia is a major trigger for non-alcoholic fatty liver disease in morbid obese
Aron-Wisnewsky, J., Minville, C., Tordjman, J., Lévy, P., Bouillot, J.-L., Basdevant, A., Bedossa, P., Clément, K., & Pépin, J.-L. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.04.022 · Cited by 255
Prevalence of Prediabetes and Diabetes and Metabolic Profile of Patients With Nonalcoholic Fatty Liver Disease (NAFLD)
Ortiz‐Lopez, C., Lomonaco, R., Orsak, B., Finch, J., Chang, Z., Kochunov, V., Hardies, J., & Cusi, K. J. (2012) · Diabetes Care · doi:10.2337/dc11-1849 · Cited by 258
Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models
Weaver, R. J., Blomme, E. A. G., Chadwick, A. E., Copple, I. M., Gerets, H. H. J., Goldring, C. E., Guillouzo, A., Hewitt, P. G., Ingelman‐Sundberg, M., Jensen, K. G., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0048-x · Cited by 261
Disruption of phospholipid and bile acid homeostasis in mice with nonalcoholic steatohepatitis
Tanaka, N., Matsubara, T., Krausz, K. W., Patterson, A. D., & Gonzalez, F. J. (2012) · Hepatology · doi:10.1002/hep.25630 · Cited by 250
Insulin dysregulation
Frank, N., & Tadros, E. M. (2013) · Equine Veterinary Journal · doi:10.1111/evj.12169 · Cited by 260
Gut microbiota and non-alcoholic fatty liver disease: new insights
Aron‐Wisnewsky, J., Gaborit, B., Dutour, A., & Clément, K. (2013) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12140 · Cited by 257
Hepatic TLR4 signaling in obese NAFLD
Sharifnia, T., Antoun, J., Verriere, T. G., Suárez, G., Wattacheril, J. J., Wilson, K. T., Peek, R. M., Abumrad, N. N., & Flynn, C. R. (2015) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00304.2014 · Cited by 250
PPAR and Oxidative Stress: Con() Catenating NRF2 and FOXO
Polvani, S., Tarocchi, M., & Galli, A. (2012) · PPAR Research · doi:10.1155/2012/641087 · Cited by 253
The circadian clock and liver function in health and disease
Mukherji, A., Bailey, S. M., Staels, B., & Baumert, T. F. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.03.020 · Cited by 246
Macrophage functional diversity in NAFLD — more than inflammation
Barreby, E., Chen, P., & Aouadi, M. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00675-6 · Cited by 251
Nonalcoholic Fatty Liver Disease: Modulating Gut Microbiota to Improve Severity?
Aron‐Wisnewsky, J., Warmbrunn, M. V., Nieuwdorp, M., & Clément, K. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.049 · Cited by 252
Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation
Bates, J., Vijayakumar, A., Ghoshal, S., Marchand, B., Yi, S., Kornyeyev, D., Zagorska, A., Hollenback, D., Walker, K., Liu, K., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.04.037 · Cited by 230
Pyrazolone structural motif in medicinal chemistry: Retrospect and prospect
Zhao, Z., Dai, X., Li, C., Wang, X. L., Tian, J., Feng, Y., Xie, J., Ma, C., Nie, Z., Fan, P., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111893 · Cited by 240
Therapies in non‐alcoholic steatohepatitis ( NASH )
Oseini, A. M., & Sanyal, A. J. (2017) · Liver International · doi:10.1111/liv.13302 · Cited by 244
Diabetes and Nonalcoholic Fatty Liver Disease: A Pathogenic Duo
Williams, K., Shackel, N. A., Gorrell, M. D., McLennan, S. V., & Twigg, S. M. (2012) · Endocrine Reviews · doi:10.1210/er.2012-1009 · Cited by 235
Mixed lineage kinase 3 mediates release of C‐X‐C motif ligand 10–bearing chemotactic extracellular vesicles from lipotoxic hepatocytes
Ibrahim, S. H., Hirsova, P., Tomita, K., Bronk, S. F., Werneburg, N. W., Harrison, S. A., Goodfellow, V. S., Malhi, H., & Gores, G. J. (2016) · Hepatology · doi:10.1002/hep.28252 · Cited by 232
Danger-Associated Molecular Patterns (DAMPs): Molecular Triggers for Sterile Inflammation in the Liver
Mihm, S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103104 · Cited by 232
Hepatic cholesterol transport and its role in non-alcoholic fatty liver disease and atherosclerosis
Li, H., Yu, X.-H., Ou, X., Ouyang, X.-P., & Tang, C. (2021) · Progress in Lipid Research · doi:10.1016/j.plipres.2021.101109 · Cited by 237
Nonalcoholic fatty liver disease in adults: current concepts in etiology, outcomes, and management
Marjot, T., Moolla, A., Cobbold, J. F., Hodson, L., & Tomlinson, J. W. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz009 · Cited by 228
Obesity-Dependent Metabolic Signatures Associated with Nonalcoholic Fatty Liver Disease Progression
Barr, J., Caballería, J., Martínez‐Arranz, I., Domínguez‐Díez, A., Alonso, C., Muntané, J., Pérez-Cormenzana, M., García‐Monzón, C., Mayo, R., Martín‐Duce, A., et al. (2012) · Journal of Proteome Research · doi:10.1021/pr201223p · Cited by 229
Bile Acid Receptor Activation Modulates Hepatic Monocyte Activity and Improves Nonalcoholic Fatty Liver Disease
McMahan, R. H., Wang, X. X., Cheng, L. L., Krisko, T., Smith, M., El Kasmi, K., Pruzanski, M., Adorini, L., Golden-Mason, L., Levi, M., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.446575 · Cited by 225
Non-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models and Medical Treatments
Peng, C. Y., Stewart, A. G., Woodman, O. L., Ritchie, R. H., & Qin, C. X. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.603926 · Cited by 239
Metabolic drivers of non-alcoholic fatty liver disease
Bence, K. K., & Birnbaum, M. J. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101143 · Cited by 230
Recent advances in the development of farnesoid X receptor agonists.
Ali, A. H., Carey, E. J., & Lindor, K. D. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2305-5839.2014.12.06 · Cited by 224
Pathogenesis of nonalcoholic steatohepatitis
Liu, W., Baker, R. D., Bhatia, T., Zhu, L., & Baker, S. S. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2161-x · Cited by 233
Liver fibrosis in NAFLD/NASH: from pathophysiology towards diagnostic and therapeutic strategies
Parola, M., & Pinzani, M. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101231 · Cited by 239
TXNIP/VDUP1 attenuates steatohepatitis via autophagy and fatty acid oxidation
Park, H.-S., Song, J.-W., Park, J.-H., Lim, B.-K., Moon, O.-S., Son, H.-Y., Lee, J.-H., Gao, B., Won, Y.-S., & Kwon, H.-J. (2021) · Autophagy · doi:10.1080/15548627.2020.1834711 · Cited by 219
Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis
Lawitz, E. J., Coste, A., Poordad, F., Alkhouri, N., Loo, N., McColgan, B. J., Tarrant, J. M., Nguyen, T., Han, L., Chung, C., et al. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.04.042 · Cited by 217
Role of Cholesterol‐Associated Steatohepatitis in the Development of NASH
Horn, C. L., Morales, A. L., Savard, C. E., Farrell, G. C., & Ioannou, G. N. (2021) · Hepatology Communications · doi:10.1002/hep4.1801 · Cited by 225
FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases
Tillman, E. J., & Rolph, T. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.601290 · Cited by 214

Authors: Neuschwander‐Tetri, B. A.
Affiliations: Saint Louis University (US)
Corresponding author: Neuschwander‐Tetri, Brent A.
ORCID: Neuschwander‐Tetri, Brent A.
Venue: Hepatology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2010-08
Volume: 52
Issue: 2
Pages: 774-788
ISSN: 0270-9139 (ISSN-L)
DOI: 10.1002/hep.23719
OpenAlex: W2107943478
Cited by: 1,077
References: 196
Citations by year: 2026: 29 · 2025: 61 · 2024: 66 · 2023: 78 · 2022: 75 · 2021: 86 · 2020: 106 · 2019: 72 · 2018: 66 · 2017: 72 · 2016: 77 · 2015: 60 · 2014: 64 · 2013: 52 · 2012: 47
FWCI: 5.87
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 1857 d)
Locations: Hepatology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
Keywords: nonalcoholic steatohepatitis, hepatic lipotoxicity, NASH pathogenesis, triglyceride accumulation, insulin resistance, de novo lipogenesis, adipose tissue insulin sensitivity, lipolysis, carbohydrate intake, physical activity, muscle glucose uptake
MeSH terms: Fatty Acids, Fatty Liver, Humans, Insulin Resistance, Liver, Causality, Oxidative Stress, Lipid Metabolism

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites†

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks